CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model

Investigational New Drugs

Volumn 32, Issue 3, 2014, Pages 400-411

  Moon, Chang Hoon ^a   Lee, Seung Ju ^a   Lee, Ho Yong ^a   Dung, Le Thi Kim ^a   Cho, Wha Ja ^a   Cha, HeeJeong ^a   Park, Jeong Woo ^b   Min, Young Joo ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan   (South Korea)

Author keywords

CKD 516; Microtubule; Vascular disrupting agent

Indexed keywords

ANTINEOPLASTIC AGENT; BENZOPHENONE DERIVATIVE; BETA TUBULIN; CKD 516; GEMCITABINE; MESSENGER RNA; TUBULIN; UNCLASSIFIED DRUG; DEOXYCYTIDINE; N-(4-(3-(1H-1,2,4-TRIAZOL-1-YL)-4-(3,4,5-TRIMETHOXYBENZOYL)PHENYL)THIAZOL-2-YL)-2-AMINO-3-METHYLBUTANAMIDE; VALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL LEVEL; CONTROLLED STUDY; DEPOLYMERIZATION; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG CARCINOMA; MALE; MICROTUBULE ASSEMBLY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR NECROSIS; TUMOR VASCULARIZATION; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; FEMALE; METABOLISM; MICROTUBULE; MUTANT MOUSE STRAIN; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOPHENONES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DEOXYCYTIDINE; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE, MUTANT STRAINS; MICROTUBULES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUBULIN; TUMOR BURDEN; VALINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904647025     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0043-8     Document Type: Article

References (29)

1. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6
2. Zetter BR (1998) Angiogenesis and tumor metastasis. Annu Rev Med 49:407-424
3. Eichhorn ME, Kleespies A, AngeleMK, JauchKW, Bruns CJ (2007) Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbecks Arch Surg 392:371-379 (Pubitemid 46675800)
4. Ergun S, Kilic N, Wurmbach JH et al (2001) Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis 4:193-206 (Pubitemid 34174308)
5. Davidoff AM, Ng CY, Brown P et al (2001) Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res 7:2870-2879 (Pubitemid 32911397)
6. Lyden D, Hattori K, Dias S et al (2001) Impaired recruitment of bone marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194-1201 (Pubitemid 33063774)
7. Cushman M, Nagarathnam D, Gopal D, Chakraborti AK, Lin CM et al (1991) Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization. J Med Chem 34:2579-2588
8. Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10:415-427
9. Moon CH, Lee SJ, Lee HY, Song HT, Min YJ et al (2013) KML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumormodel. PLoS One 8(1):e53900
10. Kavallaris M (2010) Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 3:194-204
11. Calligaris D, Verdier-Pinard P, Devred F, Villard C, Braguer D, Lafitte D (2010) Microtubule targeting agents: from biophysics to proteomics. Cell Mol Life Sci 67(7):1089-1104
12. Jordan MA, Kamath K (2007) How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 7(8):730-742
13. Lee J, KimSJ, Choi H, Kim YH, Lim ITet al (2010) Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J Med Chem 53:6337-6354
14. Palazzo A, Ackerman B, Gundersen GG (2003) Cell biology: tubulin acetylation and cell motility. Nature 421:230 (Pubitemid 36139118)
15. Infante AS, Stein MS, Zhai Y, Borisy GG, Gundersen GG (2000) Detyrosinated (Glu) microtubules are stabilized by an ATP-sensitive plus-end cap. J Cell Sci 113(Pt 22):3907-3919 (Pubitemid 32194516)
16. Kanthou C, Tozer GM (2009) Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol 90:284-294
17. Horsman MR, Siemann DW (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66:11520-11539 (Pubitemid 46094158)
18. Ching LM, Goldsmith D, Joseph WR, Körner H, Sedgwick JD et al (1999) Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6- dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 59:3304-3307 (Pubitemid 29334480)
19. Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC et al (1999) Stimulation of tumors to synthesize tumor necrosis factoralpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 59:633-638 (Pubitemid 29076061)
20. Hammers HJ, Verheul HM, Salumbides B, Sharma R, RudekMet al (2010) Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 9:1525-1535
21. Cleveland PF (1983) Elevation of tubulin levels by microinjection suppresses new tubulin synthesis. Nature 305:738-740
22. Kavallaris M, Kuo DYS, Burkhart CA et al (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 100:1282-1293 (Pubitemid 27386315)
23. Kamath K, Wilson L, Cabral F, Jordan MA (2005) βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 280:12902-12907
24. Kavallaris M, Tait AS, Walsh BJ et al (2001) Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res 61:5803-5809 (Pubitemid 32769098)
25. Galmarini CM, Kamath K, Vanier-Viornery A et al (2003) Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br J Cancer 88:1793-1799 (Pubitemid 36760426)
26. Arai K, Maruo K, Ara KY, Uehara K, Matsuda H (2001) Characterization of isotype-specific regions of five classes of canine β-tubulin and their expression in several tissues and cell culture. J Vet Med Sci 63:1297-1302 (Pubitemid 33642065)
27. Chaplin DJ, Horsman MR, Siemann DW (2006) Current development status of small-molecule vascular disrupting agents. Curr Opin Invest Drugs 7:522-528 (Pubitemid 43891030)
28. Bouzin C, Feron O (2007) Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist Updat 10:109-120 (Pubitemid 47031051)
29. Patterson DM, Rustin GJ (2007) Vascular damaging agents. Clin Oncol (R Coll Radiol) 19:443-456 (Pubitemid 46995617)